French researchers have found MALT1 blockers not only to act on blood cancers but also to be effective as a treatment for glioblastoma.
Researchers have designed a limb girdle muscular dystrophy 2A gene therapy preventing cardiotoxicity of calpain3 gene transfer.
Having secured a €2.785m grant from the EU and €4.55m from a Series B round, MaxiVAX is going full steam ahead with its Phase II cancer vaccine programmes.
Geneva-based GeNeuro SA announced a new clinical study of temelimab to treat patients with multiple sclerosis in collaboration with Karolinska Institute and ASC.
Roche AG said on Friday that its PD-L1 blocker Tecentriq plus its VEFG blocker Avastin improved progression-free survival versus sorafinib in a pivotal study in hepatocellular carcinoma (HCC) patients.
Azeria Therapeutics Ltd (Cambridge, UK) has raised a £32m (€37.3m) in a Series B financing led by Syncona Ltd contributing £29.5m (€34.4m).
GHO Capital raises €975m in largest ever European private equity healthcare fund.
Europe’s largest partnering event, the BIO-Europe, hit another visitor record on the occasion of its 25th anniversary in Hamburg.
Zelluna Immunotherapy and Glycostem Therapeutics have partnered to develop allogeneic TCR-NK therapies.
Danish Novo Nordisk A/S has secured access to Dicerna Incs GalXC RNAi technology in a R&D deal worth US$225m upfront over three years comprising 30 liver targets.